//
sign in
Profile
by @danabra.mov
Profile
by @dansshadow.bsky.social
Profile
by @jimpick.com
AviHandle
by @danabra.mov
AviHandle
by @dansshadow.bsky.social
AviHandle
by @katherine.computer
EventsList
by @katherine.computer
ProfileHeader
by @dansshadow.bsky.social
ProfileHeader
by @danabra.mov
ProfileMedia
by @danabra.mov
ProfilePlays
by @danabra.mov
ProfilePosts
by @danabra.mov
ProfilePosts
by @dansshadow.bsky.social
ProfileReplies
by @danabra.mov
Record
by @atsui.org
Skircle
by @danabra.mov
StreamPlacePlaylist
by @katherine.computer
+ new component
Profile
Loading...


Loading...
Research Fellow @flatironinstitute.org @simonsfoundation.org Formerly @csail.mit.edu @msftresearch.bsky.social @uconn.bsky.social Computational systems x structure biology | he/him | https://samsl.io | 👨🏼‍💻
Samuel Sledzieski
My go to example of this sort of thing is the study of weird thermophilic bacteria gave us PCR, upon which so much of modern biological research and its many applications (including drug discovery!) depend
We told you it wouldn’t be a long wait. 👀 Even more predicted protein structures have been added to the #AlphaFold Database. This time, the database has expanded to include heterodimers – protein complexes made up of two different proteins. alphafold.ebi.ac.uk
Everything you wanted to know about the protein chemistry behind how amino-acid changes affect the cellular abundance of proteins from @tkschulze.bsky.social Effects of residue substitutions on the cellular abundance of proteins doi.org/10.7554/eLif...
13d
15d
13d
EMBL-EBI
Wandering Scientist
Kresten Lindorff-Larsen
People often think about risk as referring to (i): Can the project achieve its specific aims? But really what NIH should want is (ii): studies with low probability of huge long-term impact. Here, think of work on gila monster venoms (leading to GLP-1 meds) or bacterial immune systems (crispr)
13d